Cilengitide in newly diagnosed glioblastoma: Biomarker expression and outcome

Oncotarget

Volumn 7, Issue 12, 2016, Pages 15018-15032

  Weller, Michael ^a   Nabors, Louis Burt ^b   Gorlia, Thierry ^c   Leske, Henning ^d   Rushing, Elisabeth ^d   Bady, Pierre ^e,f,g   Hicking, Christine ^h   Perry, James ⁱ   Hong, Yong Kil ^j   Roth, Patrick ^a   Wick, Wolfgang ^k,l   Goodman, Simon L ^h   Hegi, Monika E ^g   Picard, Martin ^h   Moch, Holger ^m   Straub, Josef ^h   Stupp, Roger ^m  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^c EORTC DATA CENTER   (Belgium)

^d UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^e UNIVERSITY OF LAUSANNE   (Switzerland)

^f SWISS INSTITUTE OF BIOINFORMATICS   (Switzerland)

^g LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^h MERCK KGAA   (Germany)

ⁱ SUNNYBROOK RESEARCH INSTITUTE   (Canada)

^j The Catholic University of Korea   (South Korea)

^k UNIVERSITY OF HEIDELBERG   (Germany)

^l GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^m UNIVERSITY HOSPITAL ZURICH   (Switzerland)

more..

Author keywords

Biomarker; Glioblastoma; Integrin; PSmad; TGF b

Indexed keywords

ALPHAVBETA5 INTEGRIN; ALPHAVBETA8 INTEGRIN; CILENGITIDE; INTEGRIN; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; SMAD2 PROTEIN; TRANSFORMING GROWTH FACTOR BETA; TUMOR MARKER; UNCLASSIFIED DRUG; VITRONECTIN RECEPTOR; SMAD2 PROTEIN, HUMAN; SNAKE VENOM;

ADULT; AGED; ARTICLE; CANCER TISSUE; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; ENDOTHELIUM CELL; FEMALE; GLIOBLASTOMA; GLIOBLASTOMA CELL LINE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; METHYLATION; MGMT GENE; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PREDICTION; PROGRESSION FREE SURVIVAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; QUANTITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL; CANCER STAGING; CLINICAL TRIAL; COHORT ANALYSIS; DRUG EFFECTS; FOLLOW UP; GENE EXPRESSION REGULATION; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; PROGNOSIS; SURVIVAL RATE; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; BIOMARKERS, TUMOR; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; GENE EXPRESSION REGULATION, NEOPLASTIC; GLIOBLASTOMA; HUMANS; INTEGRIN ALPHAVBETA3; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; RECEPTORS, VITRONECTIN; SMAD2 PROTEIN; SNAKE VENOMS; SURVIVAL RATE; YOUNG ADULT;

EID: 84962841573     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.7588     Document Type: Article

References (31)

1. Gladson CL, Cheresh DA. Glioblastoma expression of vitronectin and the alpha v beta 3 integrin. Adhesion mechanism for transformed glial cells. J Clin Invest. 1991; 88:1924-1932.
2. Schnell O, Krebs B, Carlsen J, Miederer I, Goetz C, Goldbrunner RH, Wester HJ, Haubner R, Popperl G, Holtmannspotter M, Kretzschmar HA, Kessler H, Tonn JC, et al. Imaging of integrin alpha(v)beta(3) expression in patients with malignant glioma by [18F] Galacto-RGD positron emission tomography. Neuro Oncol. 2009; 11:861-870.
3. Mikkelsen T, Brodie C, Finniss S, Berens ME, Rennert JL, Nelson K, Lemke N, Brown SL, Hahn D, Neuteboom B, Goodman SL. Radiation sensitization of glioblastoma by cilengitide has unanticipated schedule-dependency. Int J Cancer. 2009; 124:2719-2727.
4. MacDonald TJ, Taga T, Shimada H, Tabrizi P, Zlokovic BV, Cheresh DA, Laug WE. Preferential susceptibility of brain tumors to the antiangiogenic effects of an alpha(v) integrin antagonist. Neurosurgery. 2001; 48:151-157.
5. Dechantsreiter MA, Planker E, Matha B, Lohof E, Holzemann G, Jonczyk A, Goodman SL, Kessler H. N-Methylated cyclic RGD peptides as highly active and selective alpha(V)beta(3) integrin antagonists. J Med Chem. 1999; 42:3033-3040.
6. Goodman SL, Picard M. Integrins as therapeutic targets. Trends in pharmacological sciences. 2012; 33:405-412.
7. Nabors LB, Mikkelsen T, Rosenfeld SS, Hochberg F, Akella NS, Fisher JD, Cloud GA, Zhang Y, Carson K, Wittemer SM, Colevas AD, Grossman SA. Phase I and correlative biology study of cilengitide in patients with recurrent malignant glioma. J Clin Oncol. 2007; 25:1651-1657.
8. Reardon DA, Fink KL, Mikkelsen T, Cloughesy TF, O'Neill A, Plotkin S, Glantz M, Ravin P, Raizer JJ, Rich KM, Schiff D, Shapiro WR, Burdette-Radoux S, et al. Randomized phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme. J Clin Oncol. 2008; 26:5610-5617.
9. Nabors LB, Mikkelsen T, Hegi ME, Ye X, Batchelor T, Lesser G, Peereboom D, Rosenfeld MR, Olsen J, Brem S, Fisher JD, Grossman SA, New Approaches to Brain Tumor Therapy Central Nervous System C. A safety run-in and randomized phase 2 study of cilengitide combined with chemoradiation for newly diagnosed glioblastoma (NABTT 0306). Cancer. 2012; 118:5601-5607.
10. Stupp R, Hegi ME, Neyns B, Goldbrunner R, Schlegel U, Clement PM, Grabenbauer GG, Ochsenbein AF, Simon M, Dietrich PY, Pietsch T, Hicking C, Tonn JC, et al. Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma. J Clin Oncol. 2010; 28:2712-2718.
11. Nabors LB, Fink KL, Mikkelsen T, Grujicic D, Tarnawski R, Nam DH, Mazurkiewicz M, Salacz M, Ashby L, Zagonel V, Depenni R, Perry JR, Hicking C, et al. Two cilengitide regimens in combination with standard treatment for patients with newly diagnosed glioblastoma and unmethylated MGMT gene promoter: results of the open-label, controlled, randomized phase II CORE study. Neuro Oncol. 2015; 17:708-717
12. Stupp R, Hegi ME, Gorlia T, Erridge SC, Perry J, Hong YK, Aldape KD, Lhermitte B, Pietsch T, Grujicic D, Steinbach JP, Wick W, Tarnawski R, et al. Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2014; 15:1100-1108.
13. Goodman SL, Grote HJ, Wilm C. Matched rabbit monoclonal antibodies against αv-series integrins reveal a novel αvβ3-LIBS epitope, and permit routine staining of archival paraffin samples of human tumors. Biol Open. 2012; 1; 329-340
14. Riemenschneider MJ, Mueller W, Betensky RA, Mohapatra G, Louis DN. In situ analysis of integrin and growth factor receptor signaling pathways in human glioblastomas suggests overlapping relationships with focal adhesion kinase activation. Am J Pathol. 2005; 167:1379-1387.
15. Tchaicha JH, Reyes SB, Shin J, Hossain MG, Lang FF, McCarty JH. Glioblastoma angiogenesis and tumor cell invasiveness are differentially regulated by beta8 integrin. Cancer Res. 2011; 71:6371-6381.
16. Reyes SB, Narayanan AS, Lee HS, Tchaicha JH, Aldape KD, Lang FF, Tolias KF, McCarty JH. alphavbeta8 integrin interacts with RhoGDI1 to regulate Rac1 and Cdc42 activation and drive glioblastoma cell invasion. Mol Biol Cell. 2013; 24:474-482.
17. Roth P, Silginer M, Goodman SL, Hasenbach K, Thies S, Maurer G, Schraml P, Tabatabai G, Moch H, Tritschler I, Weller M. Integrin control of the transforming growth factor-beta pathway in glioblastoma. Brain. 2013; 136:564-576.
18. Silginer M, Weller M, Ziegler U, Roth P. Integrin inhibition promotes atypical anoikis in glioma cells. Cell death & disease. 2014; 5:e1012.
19. Silginer M, Burghardt I, Gramatzki D, Bunse L, Leske H, Rushing EJ, Hao N, Platten M, Weller M, Roth P. The aryl hydrocarbon receptor links integrin signaling to the TGF-beta pathway. Oncogene. 2015; Oct 26. doi: 10.1038/onc.2015.387. [Epub ahead of print].
20. Bruna A, Darken RS, Rojo F, Ocana A, Penuelas S, Arias A, Paris R, Tortosa A, Mora J, Baselga J, Seoane J. High TGFbeta-Smad activity confers poor prognosis in glioma patients and promotes cell proliferation depending on the methylation of the PDGF-B gene. Cancer Cell. 2007; 11:147-160.
21. Platten M, Wick W, Wild-Bode C, Aulwurm S, Dichgans J, Weller M. Transforming growth factors beta(1) (TGF-beta(1)) and TGF-beta(2) promote glioma cell migration via Up-regulation of alpha(V)beta(3) integrin expression. Biochem Biophys Res Commun. 2000; 268:607-611.
22. Frei K, Gramatzki D, Tritschler I, Schroeder JJ, Espinoza L, Rushing EJ, Weller M. Transforming growth factor-β pathway activity in glioblastoma. Oncotarget 2015; 6:5963-5977 doi: 10.18632/oncotarget.3467.
23. Rodon J, Carducci MA, Sepulveda-Sanchez JM, Azaro A, Calvo E, Seoane J, Brana I, Sicart E, Gueorguieva I, Cleverly AL, Pillay NS, Desaiah D, Estrem ST, et al. First-in-human dose study of the novel transforming growth factor-beta receptor I kinase inhibitor LY2157299 monohydrate in patients with advanced cancer and glioma. Clin Cancer Res. 2015; 21:553-560.
24. Schittenhelm J, Schwab EI, Sperveslage J, Tatagiba M, Meyermann R, Fend F, Goodman SL, Sipos B. Longitudinal expression analysis of alphav integrins in human gliomas reveals upregulation of integrin alphavbeta3 as a negative prognostic factor. J Neuropathol Exp Neurol. 2013; 72:194-210.
25. Cambier S, Gline S, Mu D, Collins R, Araya J, Dolganov G, Einheber S, Boudreau N, Nishimura SL. Integrin alpha(v)beta8-mediated activation of transforming growth factor-beta by perivascular astrocytes: an angiogenic control switch. Am J Pathol. 2005; 166:1883-1894.
26. Schittenhelm J, Klein A, Tatagiba MS, Meyermann R, Fend F, Goodman SL, Sipos B. Comparing the expression of integrins alphavbeta3, alphavbeta5, alphavbeta6, alphavbeta8, fibronectin and fibrinogen in human brain metastases and their corresponding primary tumors. International journal of clinical and experimental pathology. 2013; 6:2719-2732.
27. Vogetseder A, Thies S, Ingold B, Roth P, Weller M, Schraml P, Goodman SL, Moch H. alphav-Integrin isoform expression in primary human tumors and brain metastases. Int J Cancer. 2013; 133:2362-2371.
28. Kraus JA, Dabbs DJ, Beriwal S, Bhargava R. Semi-quantitative immunohistochemical assay versus oncotype DX((R)) qRT-PCR assay for estrogen and progesterone receptors: an independent quality assurance study. Mod Pathol. 2012; 25:869-876.
29. Kinsel LB, Szabo E, Greene GL, Konrath J, Leight GS, McCarty KS, Jr. Immunocytochemical analysis of estrogen receptors as a predictor of prognosis in breast cancer patients: comparison with quantitative biochemical methods. Cancer Res. 1989; 49:1052-1056.
30. Romesburg HC. Exploring, confirming and randomization tests. Computers and Geosciences. 1985; 11:19-37.
31. Dray S, Dufour AB. The ade4 package: implementing the duality diagrom for ecologists. Journal of statistical software. 2007; 22:1-20.